Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
Abstract High tumor mutation load (TMB-H, or TMB ≥ 10) has been approved by the U.S. FDA as a biomarker for pembrolizumab treatment of solid tumors, including non‑small cell lung cancer (NSCLC). Patients with cancer who have immunotherapy-resistant gene mutations cannot achieve clinical benefits eve...
Main Authors: | Xia-ye Miao, Hao Wu, Bi-cheng Ye, Qian-wen Yi, Fang-nan Lin, Yi-lin Wang, Chuan-li Ren, Yan-fang Jiang, Ang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-25050-3 |
Similar Items
-
Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma
by: Guifu Wu, et al.
Published: (2024-03-01) -
PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
by: Jiali Dai, et al.
Published: (2023-01-01) -
Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
by: Meng-Ta Sung, et al.
Published: (2022-05-01) -
TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01) -
A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors
by: Jin Liu, et al.
Published: (2022-01-01)